Galmed Pharmaceuticals Ltd. GLMD 深 滬
已收盤 06-05 16:00:00 美东时间
0.696
-0.034
-4.67%
華盛通- 最 高0.7301
- 今 開0.7301
- 成交量 12.17万股
- 最 低 0.6876
- 昨 收 0.7301
- 總市值 459.34万
- 52周最高 2.34
- 市盈率 靜 --
- 換手率 1.84%
- 52周最低 0.4111
- 委 比 5.29%
- 總股本 659.97万
- 歷史最高 4870.80
- 量 比 0.76
- 振 幅 5.82%
- 歷史最低 0.4111
- 每 手 1
- 風險率 0.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Galmed Reports Preclinical Results for Heart Disease Drug Combination, Study Identifies New Pathway Linked to Cardiac Fibrosis
Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and GI oncology diseases, today announced
06-02 19:38
Galmed Pharmaceuticals Announces Milestone Results From Phase 1 PK Study In Healthy Subjects; 400mg AM Increases Bioavailability By ~500% In Comparison To Aramchol Free Acid 300mg
Results from Study AM-001 mark a pivotal advance through the transition to a once daily lower 400mg dose of AM enabling:Production of GMP clinical batch for Galmed's upcoming clinical trialsSolidification and
05-14 19:38
Tissue Dynamics, Galmed Pharmaceuticals Partner To Develop Novel Human Chronic Fibrosis Model
Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today announced a
05-06 19:37
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Intellia Therapeutics (NASDAQ:NTLA) stock rose 19.1% to $16.23 during ...
04-25 05:05
Galmed Stock Soars On Brain-Penetrating Aramchol Formulation
Galmed Pharmaceuticals Ltd. shares are trading higher after it announced the development of a brain penetrating new formulation of Aramchol.
04-09 23:04
Galmed Pharmaceuticals shares are trading higher after the company announced the development of a brain penetrating new formulation of Aramchol.
Galmed Pharmaceuticals shares are trading higher after the company announced th...
04-09 20:39
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Galmed Pharmaceuticals (NASDAQ:GLMD) stock increased by 83.2% to $1.14...
04-09 20:05
Galmed Pharmaceuticals Receives Nasdaq Noncompliance Notice, Gets Time Through July 28 To Regain Compliance
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced that the Company
01-31 05:15
Galmed Pharma Granted Patent In South Korea For Aramchol And Rezdiffra Combination Therapy In NASH/MASH And Liver Fibrosis
The new patent granted in South Korea is added to earlier patents already granted by the United States Patent and Trademark Office (USPTO), Europe, Canada and other jurisdictions and will expire in the U.S. in July
2025-12-04 21:36
Galmed Pharmaceuticals Granted New Patent for Combination of Aramchol and Rezdiffra (Resmetirom) for MASH Treatment
Galmed Pharmaceuticals Ltd. has announced the grant of new use patents for the combination of its drug candidate Aramchol with Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for the treatment of MAS...
2025-12-04 21:30
